LFB and NanoCarrier extend work on long-acting Factor VIIa
This article was originally published in Scrip
Executive Summary
The French state-owned company LFB Biotechnologies has extended an option and research collaboration agreement with Japan's NanoCarrier to provide more time to assess a novel sustained-release formulation of its human Factor VIIa product for haemophilia.